Sunday, July 4, 2021

NICE publishes final guidance backing Jyseleca for rheumatoid arthritis

The National Institute for Health and Care Excellence (NICE) has published its final appraisal determination (FAD) recommending the use of Gilead Sciences and Galapagos’ Jyseleca (filgotinib) for the treatment of rheumatoid arthritis (RA).

The FAD means that the daily oral pill will now be available on the NHS in England for the treatment of eligible adults patients with moderate-to-severe active RA.

To be eligible, patients with moderate-to-severe RA will have had an inadequate response to intensive therapy with two or more disease-modifying anti-rheumatic drugs (DMARDs).

Over 400,000 people in the UK live with RA – a degenerative auto-immune disease that can potentially cause life-threatening complications.

The NICE recommendation for Jyseleca marks the first time in the UK that an advanced therapy has been made available to people with moderate RA.

“Being able to get the debilitating symptoms under control and ideally into remission, can be life changing and it is vital that people have the best chance of achieving this before it’s too late and permanent damage is done,” said Clare Jacklin, chief executive of the National Rheumatoid Arthritis Society (NRAS).

“For many, this [recommendation] could mean remaining in or getting back to work, fully enjoying family life or just getting on with simple things that many of us so often take for granted.  Having an opportunity for earlier intervention will lead I hope to many living a life unburdened by RA,” she added.

Source link

Stay Connected


Latest Articles

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...

Telangana caps Covid treatment charges in private hospitals

Hyderabad: The government of Telangana on Wednesday issued orders fixing treatment and investigation charges for Covid-19 in private hospitals.The state government, which had capped...